X0304 4 2011-10-14 1 0000873364 CEPHALON INC CEPH 0001066140 EGAN WILLIAM P 200 CLARENDON ST 51ST FLOOR BOSTON MA 02116 1 0 0 0 Common Stock 2011-10-14 4 D 0 21661 D 0 I By Trust Non-Qualified Stock Option 58.67 2011-10-14 4 D 0 10000 D 2006-05-15 2012-05-15 Common Stock 10000 0 D Non-Qualified Stock Option 45.23 2011-10-14 4 D 0 10000 D 2007-05-29 2013-05-29 Common Stock 10000 0 D Non-Qualified Stock Option 54.5 2011-10-14 4 D 0 10000 D 2008-05-13 2014-05-13 Common Stock 10000 0 D Non-Qualified Stock Option 44.09 2011-10-14 4 D 0 10000 D 2009-05-18 2015-05-18 Common Stock 10000 0 D Non-Qualified Stock Option 60.08 2011-10-14 4 D 0 10000 D 2010-05-17 2016-05-17 Common Stock 10000 0 D Non-Qualified Stock Option 79.99 2011-10-14 4 D 0 10000 D 2011-05-17 2017-05-17 Common Stock 10000 0 D Non-Qualified Stock Option 67.66 2011-10-14 4 D 0 10000 D 2012-05-22 2018-05-22 Common Stock 10000 0 D Non-Qualified Stock Option 66.55 2011-10-14 4 D 0 10000 D 2013-05-12 2019-05-12 Common Stock 10000 0 D Non-Qualified Stock Option 59.18 2011-10-14 4 D 0 15000 D 2014-05-20 2020-05-20 Common Stock 15000 0 D Non-Qualified Stock Option 79.85 2011-10-14 4 D 0 15000 D 2015-05-10 2021-05-10 Common Stock 15000 0 D Common Stock was converted pursuant to the Agreement and Plan of Merger, dated as of May 1, 2011, among Teva Pharmaceutical Industries Ltd., Copper Acquisition Corp. and Cephalon, Inc. (the "Merger Agreement") into the right to receive the Merger Consideration (as defined in the Merger Agreement) of $81.50 per share in cash. Options were canceled at the Effective Time of the Merger pursuant to the terms of the Merger Agreement in exchange for a cash payment for each share subject to the option equal to the difference between the Merger Consideration of $81.50 per share and the exercise price of the option. Reflects four-year anniversary from date of grant. Options vest 25% on each anniversary of grant and expire ten years from date of grant. Carolyn S. Iosca, Attorney-in-Fact for William P. Egan 2011-10-17